A Randomized, Parallel-group, Double-blind Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Vilaprisan in Subjects With Uterine Fibroids
Status: Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 21 Jan 2020
Price : $35 *
At a glance
- Drugs Vilaprisan (Primary)
- Indications Uterine leiomyoma
- Focus Registrational; Therapeutic Use
- Acronyms ASTEROID 7
- Sponsors Bayer
- 15 Jan 2020 Planned End Date changed from 13 Sep 2021 to 25 Dec 2019.
- 15 Jan 2020 Planned primary completion date changed from 13 Sep 2021 to 25 Dec 2019.
- 15 Jan 2020 Status changed from active, no longer recruiting to withdrawn prior to enrolment.